Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
AITP
MCID: THR100
MIFTS: 60

Thrombocytopenic Purpura, Autoimmune (AITP)

Categories: Blood diseases, Bone diseases, Immune diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Thrombocytopenic Purpura, Autoimmune

About this section

MalaCards integrated aliases for Thrombocytopenic Purpura, Autoimmune:

Name: Thrombocytopenic Purpura, Autoimmune 57 73 13
Idiopathic Thrombocytopenic Purpura 57 12 73 20 6 15 39 32
Autoimmune Thrombocytopenic Purpura 12 20 15 17
Immune Thrombocytopenic Purpura 57 12 58 70
Itp 57 20 58
Thrombocytopenia Due to Platelet Alloimmunization 70
Purpura, Thrombocytopenic, Idiopathic 44
Immune Thrombocytopenic Purpura; Itp 57
Thrombocytopenic Purpura Autoimmune 20
Purpura Thrombocytopenic Idiopathic 54
Primary Thrombocytopenic Purpura 12
Ideopath Thrombocytopenic Pur 12
Autoimmune Thrombocytopenia 70
Immune Thrombocytopenia 58
Idiopathic Purpura 12
Werlhof's Disease 12
Aitp 57

Characteristics:

Orphanet epidemiological data:

58
immune thrombocytopenia
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe),1-9/100000 (France); Age of onset: All ages;

OMIM®:

57 (Updated 05-Apr-2021)
Inheritance:
autosomal dominant form


HPO:

31
thrombocytopenic purpura, autoimmune:
Inheritance autosomal dominant inheritance


Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Immune diseases Blood diseases Bone diseases
See all MalaCards categories (disease lists)
ICD10: 32 33
Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:8924
OMIM® 57 188030
ICD9CM 34 287.31
MeSH 44 D016553
NCIt 50 C3446
SNOMED-CT 67 234490009
ICD10 32 D69.3
MESH via Orphanet 45 D016553
ICD10 via Orphanet 33 D69.3
UMLS via Orphanet 71 C0398650
Orphanet 58 ORPHA3002
MedGen 41 C0398650
UMLS 70 C0242584 C0272286 C0398650
Sources

Summaries for Thrombocytopenic Purpura, Autoimmune

About this section
GARD : 20 Idiopathic thrombocytopenic purpura (ITP) is a bleeding disorder characterized by too few platelets in the blood. This is because platelets are being destroyed by the immune system. Symptoms may include bruising, nosebleed or bleeding in the mouth, bleeding into the skin, and abnormally heavy menstruation. With treatment, the chance of remission (a symptom-free period) is good. Rarely, ITP may become a chronic ailment in adults and reappear, even after remission.

MalaCards based summary : Thrombocytopenic Purpura, Autoimmune, also known as idiopathic thrombocytopenic purpura, is related to thrombocytopenia due to platelet alloimmunization and thrombocytosis. An important gene associated with Thrombocytopenic Purpura, Autoimmune is FCGR2C (Fc Fragment Of IgG Receptor IIc (Gene/Pseudogene)), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Prednisone and Dexlansoprazole have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, spleen and bone, and related phenotypes are thrombocytopenia and purpura

Disease Ontology : 12 A primary thrombocytopenia that involves relatively few platelets in blood as a result of autoantibodies.

OMIM® : 57 Autoimmune thrombocytopenic purpura is characterized by a low platelet count, normal bone marrow, and the absence of other causes of thrombocytopenia. It is principally a disorder of increased platelet destruction mediated by autoantibodies to platelet-membrane antigens (George et al., 1994). (188030) (Updated 05-Apr-2021)

Wikipedia : 73 Immune thrombocytopenic purpura (ITP), also known as idiopathic thrombocytopenic purpura or immune... more...

Sources

Related Diseases for Thrombocytopenic Purpura, Autoimmune

About this section

Diseases related to Thrombocytopenic Purpura, Autoimmune via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 900)
# Related Disease Score Top Affiliating Genes
1 thrombocytopenia due to platelet alloimmunization 31.7 THPO SOCS1 SELP MPL ITGB3 ITGA2B
2 thrombocytosis 31.0 THPO SELP MPL IL11
3 acquired thrombocytopenia 30.9 THPO MPL ITGA2B IL11 GP1BA
4 purpura 30.8 THPO MPL ITGB3 ITGA2B GP1BA
5 neutropenia 30.7 THPO MPL IL11 IFNA2
6 splenic sequestration 30.6 THPO MPL ITGA2B
7 anemia, autoimmune hemolytic 30.6 SOCS1 LRBA ICOSLG CCR6
8 myelodysplastic syndrome 30.6 THPO SOCS1 MPL ITGA2B IL11 DNMT3B
9 colitis 30.5 SOCS1 IL18 IL11 ICOSLG CCR6
10 thrombocytopenia 3 30.5 THPO MPL
11 pulmonary embolism 30.5 GP6 GP1BA F8
12 evans' syndrome 30.4 THPO MPL LRBA CCR6
13 myelofibrosis 30.4 THPO SELP MPL IFNA2
14 exanthem 30.3 IL18 ICOSLG CCR6
15 thrombosis 30.3 SELP ITGB3 ITGA2B GP6 GP1BA F8
16 polycythemia vera 30.3 THPO SELP MPL ITGB3 IFNA2
17 von willebrand's disease 30.3 SELP ITGA2B GP1BA F8
18 fetal and neonatal alloimmune thrombocytopenia 30.3 ITGB3 ITGA2B GP1BA
19 acquired von willebrand syndrome 30.2 GP1BA F8
20 lymphadenitis 30.2 SOCS1 IL18 ICOSLG CCR6
21 herpes zoster 30.1 IFNA2 ICOSLG CCR6
22 thrombasthenia 30.1 SELP ITGB3 ITGA2B GP1BA
23 myocardial infarction 30.0 SELP ITGB3 ITGA2B IL18 GP6 GP1BA
24 myh-9 related disease 30.0 MPL GP1BA
25 crohn's disease 30.0 S100A8 IL18 ICOSLG CCR6
26 coronary thrombosis 30.0 SELP ITGB3 ITGA2B GP6 GP1BA
27 rosacea 30.0 S100A8 IL18 CCR6
28 aplastic anemia 30.0 THPO MPL ITGB3 ITGA2B IL18 IL11
29 dermatitis, atopic 29.9 SELP IL18 ICOSLG GATA3 CCR6
30 paroxysmal nocturnal hemoglobinuria 29.9 THPO SELP MPL
31 arteriosclerosis 29.9 SELP ITGB3 ITGA2B IL18 GP1BA
32 lipoprotein quantitative trait locus 29.9 SOCS1 SELP ITGB3 ITGA2B IL18 GP6
33 allergic disease 29.9 IL18 ICOSLG GATA3 CCR6
34 cerebrovascular disease 29.9 SELP ITGB3 ITGA2B GP1BA F8
35 x-linked recessive disease 29.9 ICOSLG F8 CCR6
36 gray platelet syndrome 29.8 SELP ITGA2B GP6
37 myeloproliferative neoplasm 29.8 THPO SOCS1 MPL ITGB3 IFNA2
38 lymphoma, mucosa-associated lymphoid type 29.8 S100A8 ICOSLG CCR6
39 leukemia, chronic myeloid 29.8 THPO SOCS1 SELP MPL ITGB3 IL11
40 hemorrhagic disease 29.8 THPO SELP MPL ITGB3 ITGA2B GP6
41 glanzmann thrombasthenia 29.7 SELP ITGB3 ITGA2B GP6 GP1BA F8
42 systemic lupus erythematosus 29.7 SOCS1 SELP S100A8 IL18 IFNA2 ICOSLG
43 common cold 29.7 SELP IFNA2 ICOSLG CCR6
44 deficiency anemia 29.5 THPO SELP RHD MPL IL11 IFNA2
45 leukemia, acute myeloid 29.5 THPO MPL ITGB3 ITGA2B ICOSLG DNMT3B
46 vascular disease 29.4 SELP ITGB3 ITGA2B IL18 GP6 GP1BA
47 essential thrombocythemia 29.4 THPO SOCS1 SELP MPL ITGB3 ITGA2B
48 bernard-soulier syndrome 29.4 THPO SELP MPL ITGB3 ITGA2B GP6
49 psoriasis 29.3 S100A8 IL18 IL11 GATA3 CCR6
50 inflammatory bowel disease 29.3 SOCS1 SELP S100A8 LRBA IL18 IL11

Graphical network of the top 20 diseases related to Thrombocytopenic Purpura, Autoimmune:



Diseases related to Thrombocytopenic Purpura, Autoimmune
Sources

Symptoms & Phenotypes for Thrombocytopenic Purpura, Autoimmune

About this section

Human phenotypes related to Thrombocytopenic Purpura, Autoimmune:

58 31 (show all 12)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 thrombocytopenia 58 31 Very frequent (99-80%) HP:0001873
2 purpura 58 Frequent (79-30%)
3 gastrointestinal hemorrhage 58 Occasional (29-5%)
4 epistaxis 58 Occasional (29-5%)
5 gingival bleeding 58 Occasional (29-5%)
6 petechiae 58 Frequent (79-30%)
7 bruising susceptibility 58 Occasional (29-5%)
8 arterial thrombosis 58 Frequent (79-30%)
9 abnormal bleeding 31 HP:0001892
10 cerebral hemorrhage 58 Very rare (<4-1%)
11 thromboembolism 58 Very frequent (99-80%)
12 platelet antibody positive 31 HP:0003454

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Apr-2021)
Heme:
thrombocytopenia
bleeding diathesis

Lab:
platelet antibody

Clinical features from OMIM®:

188030 (Updated 05-Apr-2021)

GenomeRNAi Phenotypes related to Thrombocytopenic Purpura, Autoimmune according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.58 ITGB3
2 Decreased viability GR00055-A-2 9.58 ITGB3
3 Decreased viability GR00055-A-3 9.58 ITGB3
4 Decreased viability GR00106-A-0 9.58 MPL
5 Decreased viability GR00221-A-2 9.58 ITGB3
6 Decreased viability GR00221-A-4 9.58 ITGB3
7 Decreased viability GR00240-S-1 9.58 MPL
8 Decreased viability GR00249-S 9.58 ITGB3 SOCS1
9 Decreased viability GR00386-A-1 9.58 F8 GP1BA ICOSLG ITGA2B RHD SELP
10 Decreased viability GR00402-S-2 9.58 IL11 THPO
11 Decreased human papilloma virus 16 (HPV16) pseudovirus infection GR00306-A 9.43 CCR6 DNMT3B GATA3 GP6 IL18 ITGA2B

MGI Mouse Phenotypes related to Thrombocytopenic Purpura, Autoimmune:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.03 CCR6 DNMT3B F8 GATA3 GP1BA GP6
2 homeostasis/metabolism MP:0005376 9.83 CCR6 DNMT3B F8 GATA3 GP1BA GP6
3 immune system MP:0005387 9.44 CCR6 DNMT3B F8 GATA3 GP6 IL18
Sources

Drugs & Therapeutics for Thrombocytopenic Purpura, Autoimmune

About this section

Drugs for Thrombocytopenic Purpura, Autoimmune (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 167)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
3
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
4
Azathioprine Approved Phase 4 446-86-6 2265
5
Vincristine Approved, Investigational Phase 4 2068-78-2, 57-22-7 5978
6
alemtuzumab Approved, Investigational Phase 4 216503-57-0
7
Hydroxychloroquine Approved Phase 4 118-42-3 3652
8
Morphine Approved, Investigational Phase 4 57-27-2 5288826
9
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
10
Clarithromycin Approved Phase 4 81103-11-9 84029
11
glycyrrhizin Approved, Experimental Phase 4 1405-86-3 3495
12
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
13
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453 134070
14
Enoxolone Investigational Phase 4 471-53-4 18526330
15 Antimetabolites Phase 4
16 Protective Agents Phase 4
17 Proton Pump Inhibitors Phase 4
18 Antioxidants Phase 4
19 Tubulin Modulators Phase 4
20 Antimitotic Agents Phase 4
21 Anti-Ulcer Agents Phase 4
22 Antacids Phase 4
23 Antiparasitic Agents Phase 4
24 Antiprotozoal Agents Phase 4
25
Caffeic acid Phase 4 331-39-5, 501-16-6 689043
26 Antimalarials Phase 4
27 Autoantibodies Phase 4
28 Cytochrome P-450 CYP3A Inhibitors Phase 4
29 Cytochrome P-450 Enzyme Inhibitors Phase 4
30 Tin Fluorides Phase 4
31 Calcium, Dietary Phase 4
32 Vitamins Phase 4
33 Calciferol Phase 4
34 Vasoconstrictor Agents Phase 4
35 Nutrients Phase 4
36 Micronutrients Phase 4
37 Trace Elements Phase 4
38
Calcium Nutraceutical Phase 4 7440-70-2 271
39
Pantoprazole Approved Phase 3 102625-70-7 4679
40
Selenium Approved, Investigational, Vet_approved Phase 2, Phase 3 7782-49-2
41
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
42
Dapsone Approved, Investigational Phase 3 80-08-0 2955
43
Doxycycline Approved, Investigational, Vet_approved Phase 2, Phase 3 564-25-0 54671203
44
Chlorpheniramine Approved Phase 3 132-22-9, 113-92-8 2725
45
Oseltamivir Approved Phase 3 204255-11-8, 196618-13-0 65028
46
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
47
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
48
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
49
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
50
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1

Interventional clinical trials:

(show top 50) (show all 310)
# Name Status NCT ID Phase Drugs
1 An Open-label, Prospective, Multicenter Study to Investigate the Specificity of in Vivo Antibody Binding to Red Blood Cells in Subjects With Chronic Immune Thrombocytopenic Purpura (ITP) Treated With IgPro10 (Privigen®) Who Have Shown Signs of Hemolysis Completed NCT01390649 Phase 4
2 Assessment of Platelet Function in Patients With Chronic Autoimmune Thrombocytopenic Purpura (cAITP) Treated With the Thrombopoietin Receptor (MPL) Agonist Eltrombopag. Completed NCT00888901 Phase 4 eltrombopag;corticosteroids (Aprednislon)
3 Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura Completed NCT00467571 Phase 4 lansoprazole, clarithromycin, amoxycillin
4 A Longitudinal 2-year Bone Marrow Study of Eltrombopag Olamine (SB-497115-GR) in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Completed NCT01098487 Phase 4 Eltrombopag olamine
5 The Clinical Randomized Controlled Study of Different Dose Rituximab in the Treatment of Primary Immune Thrombocytopenia Completed NCT03258866 Phase 4 Rituximab;Rituximab
6 Thrombopoietin-receptor Agonist-immunomodulation in Young Adult Primary Immune Thrombocytopenia (ITP): A Multi-center Open Label Trial With Romiplostim Completed NCT02760251 Phase 4 romiplostim
7 Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia Completed NCT03229746 Phase 4 Hydroxychloroquine;vincristine;azathioprine
8 A Prospective, Multicenter, Placebo Controlled Study on Caffeic Acid Tablet Combining High-dose Dexamethasone in Management of Adult Primary Immune Thrombocytopenia (ITP) Completed NCT02556814 Phase 4 Caffeic acid tablets;Dexamethasone;placebo
9 Multicenter, Randomized, Open, Parallel Controlled Trials Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP) Completed NCT04089267 Phase 4 TPO
10 Collection of Blood Samples From Patients With Relapsing Forms of Multiple Sclerosis (RMS) Who Have Developed Immune Thrombocytopenic Purpura (ITP) After LEMTRADA® Treatment Completed NCT03784898 Phase 4
11 High-dose Dexamethasone and Conventional Dose Prednisone, for the First-line Treatment of Adults With ITP: a Multicenter, Randomized Controlled, Clinical Trial Completed NCT01356511 Phase 4 Prednisone;Dexamethasone
12 A Prospective, Phase IV, Open-Label, Multi-Center Study Evaluating Changes in Bone Marrow Morphology in Adult Subjects Receiving Romiplostim for the Treatment of Thrombocytopenia Associated With Immune (Idiopathic) Thrombocytopenia Purpura (ITP) Completed NCT00907478 Phase 4
13 A Multisite, Randomized, Double-Blind, Placebo-Controlled, and Parallel Study to Evaluate the Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia (Qi Yin Deficiency) Recruiting NCT03201848 Phase 4 Placebo;Huaiqihuang Granule
14 A Multicenter, Randomized, Open-label Study To Compare The Efficacy And Safety Of Eltrombopag Combining Rituximab With Eltrombopag In Adult ITP Patients Recruiting NCT04518475 Phase 4 eltrombopag combining rituximab;eltrombopag
15 Effects of Helicobacter Pylori Eradication Therapy in Children With Chronic Immune Thrombocytopenic Purpura Recruiting NCT03172676 Phase 4 Amoxicillin 50 mg/kg/day in 2 divided doses for 14 days.;Clarithromycin 15 mg/kg/day in 2 divided doses for 14 days.;Proton pump inhibitor 1 mg/kg/day in 2 divided doses 1 month
16 Post-Marketing Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP) Recruiting NCT03866798 Phase 4
17 Efficacy and Safety of rhTPO and Eltrombopag in the Treatment of Chinese Adults With Primary Immune Thrombocytopenia (ITP):a Multicenter, Double-blind, Randomized, Controlled Trial Recruiting NCT03771378 Phase 4 rhTPO;eltrombopag
18 Prospective, Multi-center, Open-label Study Measuring Safety and Treatment Satisfaction in Adult Subjects With Chronic Immune Thrombocytopenia (ITP) After Switching to Avatrombopag From Eltrombopag or Romiplostim Recruiting NCT04638829 Phase 4 Avatrombopag Oral Tablet
19 A Single-center Prospective Randomized Study of Atorvastatin in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP) Recruiting NCT03692754 Phase 4 Atorvastatin 20mg;Atorvastatin 10mg
20 A Single-center Prospective Randomized Study of Glycyrrhetinic Acid Combined With Dexamethasone in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP) Recruiting NCT03998982 Phase 4 Glycyrrhetinic Acid;Dexamethasone
21 Rate of Prolonged Response After Stopping Thrombopoietin-receptor Agonists Treatment in Immune Thrombocytopenia: a Prospective Multicenter Open Study Recruiting NCT03119974 Phase 4 Tpo-RA discontinuation
22 Study 200170: A Rollover Study to Provide Continued Treatment With Eltrombopag Active, not recruiting NCT01957176 Phase 4 ELT
23 Efficacy of Eltrombopag in Chronic Immune Thrombocytopenia in Pediatrics Not yet recruiting NCT04102033 Phase 4 Eltrombopag
24 A Multicenter Randomized Open-label Clinical Trial of Vitamin D Combined With HD-DXM Versus HD-DXM for the Treatment of ITP Not yet recruiting NCT04094805 Phase 4 Rocaltrol;Dexamethasone
25 Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP): a Prospective, Randomized Controlled Trial Withdrawn NCT02642380 Phase 4 Dexamethasone (4 cycles);Dexamethasone (1 cycle)
26 Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP)in Pregnancy: a Single-center Clinical Trial Unknown status NCT02270801 Phase 3 rhTPO
27 A Multicenter Prospective Randomized Study of Rituximab Combined With Bortezomib Versus Rituximab in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP) Unknown status NCT03443570 Phase 3 Rituximab;Bortezomib
28 Association of FC Gamma RIIIA Polymorphism and Thrombopoietin (THPO) Expression With Response to TPO Agonists in Refractory ITP and the Impact of Therapy on B and T Cells Subsets in the Patients With Mutated Genotypes Unknown status NCT02877212 Phase 3 Eltrombopag
29 Efficacy of Helicobacter Pylori Eradication for the Treatment of Chronic or Persistent Immune Thrombocytopenic Purpura Patients With Moderate Thrombocytopenia: Multicenter Prospective Randomized Phase 3 Study Unknown status NCT03177629 Phase 3 treatment : H. pylori eradication
30 A Phase III,Multicentre, Randomized, Double-Blind and Open-Label Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Patients With Idiopathic Thrombocytopenic Purpura Unknown status NCT03222843 Phase 3 Hetrombopag Olamine;matching placebo
31 Evaluation of Oxidant Status in Patients With Immune Thrombocytopenia (ITP) and the Role of an Adjuvant Antioxidant Therapy Unknown status NCT01763658 Phase 2, Phase 3 Antox tablets(Mepaco)
32 A Multicenter Randomized Study of Dexamethasone Combined With Rituximab, Cyclosporin and Intravenous Immunoglobulin in the Management of Newly Diagnosed ITP Patients Unknown status NCT02834468 Phase 3 DEX Combined With RTX, CSA and IVIG
33 Thrombocytopenia in Gestational Period Unknown status NCT02751593 Phase 2, Phase 3 Dexamethasone
34 Prospective Multicenter Randomized Open-label Controlled Trial Assessing Efficacy and Safety of DAPSone as a Second-line Option in Adult Immune Thrombocytopenia Unknown status NCT02627417 Phase 3 Dapsone (Disulone®);Prednisone (Cortancyl®) alone followed by monitoring and "standard of care";Prednisone (Cortancyl®)
35 A Multicenter, Single-Arm, Open Label Study Evaluating the Efficacy and Safety of Maintenance Treatment With Recombinant Human Thrombopoietin in Thrombocytopenic Subjects With Immune Thrombocytopenia Unknown status NCT01805648 Phase 3 rhTPO
36 An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Completed NCT00508820 Phase 3
37 A Randomized, Controlled, Open-label Study Evaluating the Efficacy and Tolerability of AMG 531 Versus Medical Standard of Care as Chronic Therapy for Non-splenectomized Subjects With Immune (Idiopathic) Thrombocytopenic Purpura Completed NCT00415532 Phase 3 Medical Standard of Care for ITP
38 A Two Part, Double-blind, Randomized, Placebo-controlled and Open-label Study to Investigate the Efficacy, Safety and Tolerability of Eltrombopag, a Thrombopoietin Receptor Agonist, in Pediatric Patients With Previously Treated Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP). PETIT2: Eltrombopag in PEdiatric Patients With Thrombocytopenia From ITP Completed NCT01520909 Phase 3 Eltrombopag;Placebo
39 Randomized Study of the Treatment of Primary Immune Thrombocytopenic Purpura (ITP) in Newly Diagnosed Untreated Adult Patients. Comparison of Standard Dose Prednisone Versus High-dose Dexamethasone. Completed NCT00657410 Phase 3 dexamethasone;prednisone
40 Helicobacter Pylori Infection and Chronic Immune Thrombocytopenic Purpura in Children and Adolescents - A Randomized Controlled Trial Completed NCT01730352 Phase 2, Phase 3 H. pylori triple therapy
41 EXTEND (Eltrombopag Extended Dosing Study): An Extension Study of Eltrombopag Olamine (SB-497115-GR) in Adults, With Idiopathic Thrombocytopenic Purpura (ITP), Previously Enrolled in an Eltrombopag Study. Completed NCT00351468 Phase 3 eltrombopag olamine (SB-497115-GR)
42 A Multicenter Open-labeled Pilot Study on Recombinant Human Thrombopoietin in Management of Immune Thrombocytopenia in Pregnancy Completed NCT02391272 Phase 3 rhTPO
43 An Open-label, Multicenter Study on the Efficacy and Safety of IgPro10 in Patients With Chronic Immune Thrombocytopenic Purpura (ITP) Completed NCT00168038 Phase 3
44 Clinical Study to Evaluate the Efficacy and Safety of Octagam® 10% in Idiopathic Thrombocytopenic Purpura in Adults Completed NCT00426270 Phase 3 Octagam 10%
45 Clinical Trial to Evaluate the Efficacy and the Safety of IGIV3I Grifols 10% (Human Intravenous Immunoglobulin) in Patients Diagnosed With Immune Thrombocytopenic Purpura Completed NCT00699140 Phase 3
46 A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura Completed NCT00511147 Phase 3
47 Treatment of thromBocytopenia With EltRombopag or Intravenous Immune Globulin (IVIG) Before and DurING Invasive Procedures in Patients With Immune ThrombocytoPenia- BRIDGING ITP Study Completed NCT01621204 Phase 3 Eltrombopag;IVIG infusion
48 A Phase 3 Randomized, Double Blind, Placebo Controlled Study to Determine the Safety and Efficacy of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP) Completed NCT01444417 Phase 3 Romiplostim;Placebo
49 Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)-An Extension Study of Eltrombopag in Subjects, With Idiopathic Thrombocytopenic Purpura (ITP), Previously Enrolled in an Eltrombopag Study TRA108109 (NCT00540423)-<Phase III Study> Completed NCT00828750 Phase 3 Eltrombopag oral tablets
50 Efficacy and Safety of IVIG-L (Human Normal Immunoglobulin for Intravenous Use)in Idiopathic Thrombocytopenic Purpura (ITP)Patients Completed NCT00151840 Phase 3 IVIG-L

Search NIH Clinical Center for Thrombocytopenic Purpura, Autoimmune

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Azathioprine
Cyclophosphamide
Immunoglobulins, Intravenous
Intramuscular immunoglobulin
Rho(D) Immune Globulin, human
Venoglobulin-I
Vinblastine
Vinblastine Sulfate

Cochrane evidence based reviews: purpura, thrombocytopenic, idiopathic

Sources

Genetic Tests for Thrombocytopenic Purpura, Autoimmune

About this section
Sources

Anatomical Context for Thrombocytopenic Purpura, Autoimmune

About this section

MalaCards organs/tissues related to Thrombocytopenic Purpura, Autoimmune:

40
Bone Marrow, Spleen, Bone, T Cells, Liver, Lung, B Cells
Sources

Publications for Thrombocytopenic Purpura, Autoimmune

About this section

Articles related to Thrombocytopenic Purpura, Autoimmune:

(show top 50) (show all 4481)
# Title Authors PMID Year
1
Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura. 61 57
17827395 2008
2
Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicated chronic ITP cases in Japan. 61 57
15765787 2005
3
Historical aspects and present knowledge of idiopathic thrombocytopenic purpura. 57 61
12472565 2002
4
Chronic idiopathic thrombocytopenic purpura. 57 61
7935660 1994
5
Idiopathic thrombocytopenic purpura in two elderly siblings. 57 61
4074042 1985
6
Helicobacter pylori eradication shifts monocyte Fcgamma receptor balance toward inhibitory FcgammaRIIB in immune thrombocytopenic purpura patients. 57
18654664 2008
7
Immune thrombocytopenic purpura. 57
11919310 2002
8
Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. 57
9742983 1998
9
Autoimmune thrombocytopenic purpura. 57
2413550 1985
10
Chronic immune thrombocytopenic purpura in monozygotic twins: genetic factors predisposing to ITP. 57
6890627 1982
11
Specificity of autoantibodies in autoimmune thrombocytopenia. 57
7032627 1982
12
Hereditary autoimmune thrombocytopenic purpura: an immunologic and genetic study. 57
7195175 1981
13
Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. 57
14850832 1951
14
Review article: second-generation thrombopoietin agents for treatment of chronic idiopathic thrombocytopenic purpura in adults. 61 54
19525300 2010
15
[Expression of T-bet and GATA3 in children with acute idiopathic thrombocytopenic purpura]. 61 54
20113630 2010
16
High-dose dexamethasone regulates interleukin-18 and interleukin-18 binding protein in idiopathic thrombocytopenic purpura. 61 54
19797730 2009
17
New treatments for idiopathic thrombocytopenic purpura: rethinking old hypotheses. 61 54
19426124 2009
18
Interleukin 18 and interleukin 18 binding protein in patients with idiopathic thrombocytopenic purpura. 54 61
19077159 2009
19
Romiplostim. 61 54
19275274 2009
20
Single nucleotide polymorphism in DNMT3B promoter and the risk for idiopathic thrombocytopenic purpura in Chinese population. 61 54
18437543 2008
21
[Expression of co-stimulatory molecules and role of interleukin 18 in peripheral lymphocytes of patients with idiopathic thrombocytopenic purpura]. 61 54
17605869 2007
22
Immune response to CagA protein is associated with improved platelet count after Helicobacter pylori eradication in patients with idiopathic thrombocytopenic purpura. 54 61
17241299 2007
23
Prolonged thrombocytopenia after allogeneic hematopoietic stem cell transplantation: associations with impaired platelet production and increased platelet turnover. 61 54
16915226 2006
24
Novel heterozygous missense mutation in the second leucine rich repeat of GPIbalpha affects GPIb/IX/V expression and results in macrothrombocytopenia in a patient initially misdiagnosed with idiopathic thrombocytopenic purpura. 61 54
16519708 2006
25
[Curative effect of interleukin 11 on chronic idiopathic thrombocytopenic purpura]. 54 61
16584619 2006
26
Multiple cycles of recombinant human thrombopoietin therapy in a patient with chronic refractory idiopathic thrombocytopenic purpura. 54 61
15870550 2005
27
Increased glycocalicin index and normal thrombopoietin levels in patients with idiopathic thrombocytopenic purpura with a decreased rate of platelet production. 61 54
15921398 2005
28
Danazol, idiopathic thrombocytopenic purpura, and thrombopoietin. 54 61
15629743 2004
29
Anti-GPVI-associated ITP: an acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FcRgamma-chain complex from the human platelet surface. 61 54
15150079 2004
30
[A multi-center clinical trial of recombinant human thrombopoietin in chronic refractory idiopathic thrombocytopenic purpura]. 54 61
15355668 2004
31
Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori-associated chronic idiopathic thrombocytopenic purpura. 61 54
14675413 2004
32
[Interleukin-18 and its related cytokines in plasma of patients with idiopathic thrombocytopenic purpura]. 61 54
14706156 2003
33
Soluble P-selectin, interleukin 6, and thrombopoietin levels in children with acute and chronic idiopathic thrombocytopenic purpura and their relationship with mega-dose methylprednisolone therapy: a pilot study. 61 54
12468916 2002
34
Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. 61 54
12411315 2002
35
[Study on the relations between HLA-DRB1 alleles and idiopathic thrombocytopenic purpura in children]. 54 61
12170464 2002
36
Autoantibody to c-Mpl (thrombopoietin receptor) in systemic lupus erythematosus: relationship to thrombocytopenia with megakaryocytic hypoplasia. 54 61
12209520 2002
37
Plasma thrombopoietin levels in patients with aplastic anemia and idiopathic thrombocytopenic purpura. 54 61
12150725 2002
38
The potential role of thrombopoietin in idiopathic thrombocytopenic purpura. 61 54
11913997 2002
39
[The effects of thrombopoietin and interleukin-11 on bone marrow megakaryocytic progenitors in patients with chronic idiopathic thrombocytopenic purpura in vitro]. 61 54
12528552 2001
40
[The relativity study of thrombopoietin and chronic idiopathic thrombocytopenic purpura]. 61 54
11758228 2001
41
Colony-forming unit-megakaryocyte (CFR-meg) numbers and serum thrombopoietin concentrations in thrombocytopenic disorders: an inverse correlation in myelodysplastic syndromes. 61 54
11021750 2000
42
[Clinical study on interferon treatment of chronic idiopathic thrombocytopenic purpura]. 54 61
12545843 2000
43
[The sensitivity, specificity and predictive value of PAIgG, reticulated platelets, thrombopoietin levels, and platelet size for the differential diagnosis of thrombocytopenia]. 61 54
10624125 1999
44
Serum levels of thrombopoietin, IL-11, and IL-6 in pediatric thrombocytopenias. 61 54
10525827 1999
45
Systemic causes of excessive uterine bleeding. 61 54
10513767 1999
46
Concentrations of thrombopoietin in bone marrow in normal subjects and in patients with idiopathic thrombocytopenic purpura, aplastic anemia, and essential thrombocythemia correlate with its mRNA expression of bone marrow stromal cells. 54 61
9639498 1998
47
Evaluation of thrombopoiesis in thrombocytopenic disorders by simultaneous measurement of reticulated platelets of whole blood and serum thrombopoietin concentrations. 61 54
9657432 1998
48
Plasma thrombopoietin levels in thrombocytopenic states: implication for a regulatory role of bone marrow megakaryocytes. 61 54
9633881 1998
49
Increased thrombopoietin levels in idiopathic thrombocytopenic purpura patients with a poor response to steroid therapy. 54 61
9690802 1998
50
Blood thrombopoietin, IL-6 and IL-11 levels in patients with agnogenic myeloid metaplasia. 61 54
9369414 1997
Sources

Variations for Thrombocytopenic Purpura, Autoimmune

About this section

ClinVar genetic disease variations for Thrombocytopenic Purpura, Autoimmune:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 SOCS1 NM_003745.1(SOCS1):c.368C>G (p.Pro123Arg) SNV Likely pathogenic 977212 GRCh37: 16:11348968-11348968
GRCh38: 16:11255111-11255111
2 SOCS1 NM_003745.1(SOCS1):c.24del (p.Ala9fs) Deletion Likely pathogenic 977213 GRCh37: 16:11349312-11349312
GRCh38: 16:11255455-11255455
3 SOCS1 NM_003745.1(SOCS1):c.476_480dup (p.Met161fs) Microsatellite Likely pathogenic 977214 GRCh37: 16:11348855-11348856
GRCh38: 16:11254998-11254999

Copy number variations for Thrombocytopenic Purpura, Autoimmune from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 21699 1 160500000 165500000 Copy number FCGR2C Idiopathic thrombocytopenic purpura
2 46119 10 77700000 82000000 Copy number BMPR1A Idiopathic thrombocytopenic purpura
3 121460 18 43500000 48200000 Copy number SMAD4 Idiopathic thrombocytopenic purpura
Sources

Expression for Thrombocytopenic Purpura, Autoimmune

About this section
Search GEO for disease gene expression data for Thrombocytopenic Purpura, Autoimmune.
Sources

Pathways for Thrombocytopenic Purpura, Autoimmune

About this section

Pathways related to Thrombocytopenic Purpura, Autoimmune according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 13.86 SOCS1 S100A8 ITGB3 ITGA2B IL18 IL11
2
TGF-Beta Pathway 63
Show member pathways
 13.32 THPO SOCS1 MPL ITGB3 ITGA2B IL18
3
Cytokine Signaling in Immune system 65
Show member pathways
 13.15 SOCS1 ITGB3 ITGA2B IL18 IL11 IFNA2
4
Response to elevated platelet cytosolic Ca2+ 65
Show member pathways
 12.73 THPO SELP MPL ITGB3 ITGA2B IFNA2
5
JAK-STAT signaling pathway 36
Show member pathways
 12.12 THPO SOCS1 MPL IL11 IFNA2
6
ECM-receptor interaction 36
Show member pathways
 11.9 ITGB3 ITGA2B GP6 GP1BA
7
Platelet activation 36
11.76 ITGB3 ITGA2B GP6 GP1BA
8
Hematopoietic cell lineage 36
11.65 THPO ITGB3 ITGA2B IL11 GP1BA
9
Innate Lymphoid Cell Differentiation Pathways 64
11.59 IL18 GATA3 CCR6
10
Integrin alphaIIb beta3 signaling 65
Show member pathways
 11.54 THPO MPL ITGB3 ITGA2B GP1BA
11
IL4-mediated signaling events 1
11.43 SOCS1 SELP ITGB3
12
Platelet Aggregation Inhibitor Pathway, Pharmacodynamics 60
11.32 ITGB3 ITGA2B GP6
13
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.23 THPO MPL ITGB3 ITGA2B IL11 IFNA2
14
G-protein signaling_Rap2B regulation pathway 23
10.85 THPO ITGB3 ITGA2B IL18 IL11
15
Platelet Adhesion to exposed collagen 65
10.65 GP6 GP1BA
Sources

GO Terms for Thrombocytopenic Purpura, Autoimmune

About this section

Cellular components related to Thrombocytopenic Purpura, Autoimmune according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.8 SELP RHD ITGB3 GP6 GP1BA FCGR2C
2 extracellular space GO:0005615 9.76 THPO SELP S100A8 IL18 IL11 IFNA2
3 cell surface GO:0009986 9.43 MPL ITGB3 ITGA2B GP6 GP1BA CCR6
4 platelet alpha granule membrane GO:0031092 8.8 SELP ITGB3 ITGA2B

Biological processes related to Thrombocytopenic Purpura, Autoimmune according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 humoral immune response GO:0006959 9.67 IFNA2 GATA3 CCR6
2 hemostasis GO:0007599 9.65 GP6 GP1BA F8
3 cytokine-mediated signaling pathway GO:0019221 9.63 SOCS1 MPL IL18 IL11 IFNA2 GATA3
4 platelet degranulation GO:0002576 9.62 SELP ITGB3 ITGA2B F8
5 platelet activation GO:0030168 9.56 ITGB3 GP6 GP1BA F8
6 blood coagulation, intrinsic pathway GO:0007597 9.54 GP1BA F8
7 regulation of cytokine production GO:0001817 9.54 SOCS1 ICOSLG GATA3
8 leukocyte migration involved in inflammatory response GO:0002523 9.52 S100A8 CCR6
9 positive regulation of leukocyte migration GO:0002687 9.51 SELP ITGA2B
10 lymphocyte migration GO:0072676 9.46 GATA3 CCR6
11 thrombopoietin-mediated signaling pathway GO:0038163 9.43 THPO MPL
12 chemokine production GO:0032602 9.4 S100A8 IL18
13 platelet aggregation GO:0070527 9.26 MPL ITGB3 ITGA2B GP1BA
14 blood coagulation GO:0007596 9.1 ITGB3 IFNA2 GP6 GP1BA GATA3 F8

Molecular functions related to Thrombocytopenic Purpura, Autoimmune according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.13 SOCS1 SELP S100A8 RHD MPL LRBA
2 cytokine activity GO:0005125 9.26 THPO IL18 IL11 IFNA2
3 fibrinogen binding GO:0070051 8.62 ITGB3 ITGA2B
Sources

Sources for Thrombocytopenic Purpura, Autoimmune

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....